Table 3.
Tracer(s) | Patient number |
Disease stage | Study objective |
Sensitivity | Specificity | Year | Group |
---|---|---|---|---|---|---|---|
11C-acetate | 30 | Early | Staging | NA | NA | 2002 | Kato T, et al. |
11C-acetate | 31 | Advanced | Re-staging | 83% | NA | 2002 | Kotzerke J, et al. |
11C-acetate | 20 | Advanced | Restaging | 75% | NA | 2006 | Sanblom G, et al. |
11C-acetate | 50 | Advanced | Re-staging | NA | NA | 2006 | Wachter S, et al. |
11C-acetate | 32 | Advanced | Restaging | 82% | NA | 2007 | Albrecht S, et al. |
11C-acetate | 12 | Advanced | Staging | NA | NA | 2009 | Seppala J, et al. |
11C-acetate, 11C-choline | 12 | Advanced | Staging | NA | NA | 2003 | Kotzerke J, et al. |
11C-acetate, 18F-FDG | 25 (15) | Mixed | Staging | NA | NA | 2003 | Fricke E, et al |
11C-acetate, 18F-FDG | 22(18) | Early | Staging | NA | NA | 2002 | Oyama N, et al. |
11C-acetate, 18F-FDG | 46 | Advanced | Restaging | NA | NA | 2003 | Oyama N, et al. |
11C-acetate, 18F-FCH | 11 (11) | Advanced | Restaging | NA | NA | 2007 | Vees H, et al. |